In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans

@article{Costa1990InVC,
  title={In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans},
  author={Durval C. Costa and Nicolaas Paul L.G. Verhoeff and Ian D Cullum and Peter Joseph Ell and G. M. Shah Syed and John H. Barrett and Eleni Palazidou and Brian Toone and E. Van Royen and Marcel Bobeldijk},
  journal={European Journal of Nuclear Medicine},
  year={1990},
  volume={16},
  pages={813-816}
}
3-Iodo-6-methoxybenzamide (123I-IBZM), a new Dopamine D2 receptor ligand, was used in conjunction with SME 810 brain tomography to study six subjects (one normal volunteer, four schizophrenics and one DAT patient). Initial Dynamic SPET was followed by multislice SPET. High-resolution images of the D2 receptor distribution in the basal ganglia were obtained. The specific binding in D2 receptors of the basal ganglia is highest from 2–4 h p.i. Patients on anti-psychotic drugs showed significantly… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Reduced striatal D2 receptor binding in myoclonus–dystonia

  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2008
VIEW 1 EXCERPT
CITES METHODS

References

Publications referenced by this paper.
SHOWING 1-3 OF 3 REFERENCES

Imaging of the basal ganglia in the human brain with 1-123IBZM: anew CNS D2 receptor agent

A Alavi, MG Velchik, +8 authors J Reilley
  • J Nucl Med
  • 1989
VIEW 1 EXCERPT

In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1989
VIEW 1 EXCERPT